These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 12818205)

  • 1. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
    Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
    J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment.
    Asano R; Kudo T; Nishimura Y; Makabe K; Hayashi H; Suzuki M; Tsumoto K; Kumagai I
    J Biochem; 2002 Dec; 132(6):903-9. PubMed ID: 12473192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.
    Le Gall F; Reusch U; Little M; Kipriyanov SM
    Protein Eng Des Sel; 2004 Apr; 17(4):357-66. PubMed ID: 15126676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase.
    Atwell JL; Pearce LA; Lah M; Gruen LC; Kortt AA; Hudson PJ
    Mol Immunol; 1996 Dec; 33(17-18):1301-12. PubMed ID: 9171890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D; Jimenez X; Witte L; Zhu Z
    Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains.
    Kim YJ; Neelamegam R; Heo MA; Edwardraja S; Paik HJ; Lee SG
    J Microbiol Biotechnol; 2008 Jun; 18(6):1186-90. PubMed ID: 18600066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.
    Connelly RJ; Hayden MS; Scholler JK; Tsu TT; Dupont B; Ledbetter JA; Kanner SB
    Int Immunol; 1998 Dec; 10(12):1863-72. PubMed ID: 9885907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remodeling domain interfaces to enhance heterodimer formation.
    Zhu Z; Presta LG; Zapata G; Carter P
    Protein Sci; 1997 Apr; 6(4):781-8. PubMed ID: 9098887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen.
    Jäger M; Plückthun A
    J Mol Biol; 1999 Feb; 285(5):2005-19. PubMed ID: 9925781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
    Kipriyanov SM; Moldenhauer G; Strauss G; Little M
    Int J Cancer; 1998 Aug; 77(5):763-72. PubMed ID: 9688311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment.
    Arndt KM; Müller KM; Plückthun A
    Biochemistry; 1998 Sep; 37(37):12918-26. PubMed ID: 9737871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv.
    Korn T; Nettelbeck DM; Völkel T; Müller R; Kontermann RE
    J Gene Med; 2004 Jun; 6(6):642-51. PubMed ID: 15170735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of a diabody, a bivalent antibody fragment.
    Perisic O; Webb PA; Holliger P; Winter G; Williams RL
    Structure; 1994 Dec; 2(12):1217-26. PubMed ID: 7704531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv.
    Whitlow M; Filpula D; Rollence ML; Feng SL; Wood JF
    Protein Eng; 1994 Aug; 7(8):1017-26. PubMed ID: 7809028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: production of bivalent and biotinylated miniantibodies.
    Kipriyanov SM; Dübel S; Breitling F; Kontermann RE; Little M
    Mol Immunol; 1994 Oct; 31(14):1047-58. PubMed ID: 7935496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies.
    Atwell JL; Breheney KA; Lawrence LJ; McCoy AJ; Kortt AA; Hudson PJ
    Protein Eng; 1999 Jul; 12(7):597-604. PubMed ID: 10436086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.